Lyon, the 15th April 2022
PRESS RELEASE

EUROFINS BIOMNIS NOW OFFERING ONCOGENETIC EXOME SEQUENCING

Cancer is a common disease that may affect approximately 1 in 5 men and 1 in 6 women around the world at some point during their lifetime[1]. It is currently estimated that 5% to 10% of cancers may be linked to hereditary genetic mutations[2]. In order to identify these genetic predispositions, Eurofins Biomnis, European leader in specialised clinical diagnostics , is now offering oncogenetic exome sequencing using Next Generation Sequencing. This comprehensive analysis can help clinicians make a molecular diagnosis and adjust the treatment and monitoring of patients and their families accordingly.

Eurofins Biomnis is committed to offering clinicians information about their patients' diseases that is increasingly precise, personalised and rapid. By offering oncogenetic exome sequencing, the laboratory allows them to quickly make a diagnosis, assess the prognosis and potentially propose an appropriate targeted therapy. This confirms Eurofins Biomnis' position in personalised, preventive and theranostic medicine, standing alongside healthcare professionals.

Sequencing to take better care of patients suffering from hereditary forms of cancer and their relatives...

Thanks to the work of the Eurofins Biomnis' team of clinical pathologists, it is now possible for clinicians and/or oncogeneticists to quickly screen a patient to determine whether they carry a known constitutional predisposition, at a low cost. Exome sequencing is an additional tool available to healthcare professionals. It can be prescribed for the vast majority of oncogenetic indications and in particular in cases where there is no family history suggestive of cancer, previously negative test results or even in cases where other genetic diseases are suspected in the family (such as polycystic kidney disease). Informed consent from the patient is required to perform the sequencing and, in addition, depending on the family context, the clinician may

[1] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018), Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68: 394-424.

[2] Institut National du cancer, prédispositions génétiques. https://www.e-cancer.fr/Patients-et-proches/Les-cancers/Cancer-du-sein/Facteurs-de-risque/Predispositions-genetiques

also propose exome sequencing for relatives, which would assist with the classification of mutations detected and with identifying other relatives carrying them in order to offer them adapted treatment if necessary.

... but also create a database useful for long-term care and research.

Exome sequencing is an effective diagnostic tool, especially over the long term. Medical knowledge is rapidly improving and new genes are regularly identified and reported in scientific publications as giving a genetic predisposition. Since all genes are sequenced in exome sequencing, this make it possible to look back over earlier data. This means that an exome which may be negative initially (meaning that it does not identify a mutation in a gene that is validated as being involved in a genetic predisposition), could become positive at a later date as medical knowledge advances. Exome sequencing also allows the creation of a combined database of results that is useful for interpreting known mutations and identifying new genes.

Eurofins Biomnis standing with clinicians: tailored assistance

Every case file is examined by two different members of laboratory staff, in order to ensure the highest degree of reliability of the information provided. All case files are discussed by a team including at least one clinical pathologist and the clinician, to validate the results and the report. Depending on the context, opinions may be sought from the expert centre.

CLINICAL CASE STUDY
Female patient, aged 80, with a personal history of breast cancer at the age of 42 and again at 80. Family history of breast cancer in her two daughters and mother. The exome of the patient and one of her daughters identified a genetic predisposition to cancer. The clinical pathologist thus recommended that potentially affected member of the family continue to be tested, in order to propose adapted treatment according to the current recommendations.

Exome sequencing at Eurofins Biomnis:

Exceptional performance:
- 10X coverage ~ 99.5%
- 30X coverage ~ 99%
- 50x coverage ~ 98%

Multiple specialities
- Nephrology
- Pre- and postnatal cardiology
- Mental disability
- Oncogenetics
- and more...

Eurofins Biomnis press contact
Wellcom Agency
Gaëlle Ryouq, Héloïse Sintes, Anaïs Ranouil
biomnis@wellcom.fr
(+33) 01 46 34 60 60

About Eurofins Biomnis

European leader in the sector of specialised clinical pathology, Eurofins Biomnis carries out over 39,000 analyses per day from a range of over 3,000 available tests, including specialised tests for which the company has the appropriate authorisations. Founded in 1897 by Marcel Mérieux, Eurofins Biomnis is the leader in specialised clinical pathology in France. It has maintained this leading position through continuous technological innovation and investment, particularly in areas such as female biology, oncology and personalised medicine, as well as chromosomal and molecular genetics. With 125 years of expertise and innovation in the service of clinical pathology, Eurofins Biomnis forms the core of the Clinical Diagnostics division of the Eurofins Group in Europe and is actively expanding in worldwide markets.
www.eurofins-biomnis.com

About Eurofins - the world leader in bio-analysis

About Eurofins - the world leader in bio-analysis, Eurofins performs analyses to save lives. With a workforce of over 58,000 persons and a network of over 900 laboratories in over 54 countries, the companies of the Eurofins Group offer a rich portfolio of over 200,000 analytical methods. Eurofins Scientific shares are listed on the Euronext Paris exchange.